CAS NO: | 100986-85-4 |
包装: | 25mg |
市场价: | 536元 |
Cas No. | 100986-85-4 |
别名 | 左氧氟沙星; (-)-Ofloxacin |
化学名 | (S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid |
Canonical SMILES | FC1=C(C2=C(C3=C1[H])N(C([H])=C(C(O[H])=O)C3=O)[C@](C([H])([H])[H])([H])C([H])([H])O2)N4C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C4([H])[H] |
分子式 | C18H20FN3O4 |
分子量 | 361.37 |
溶解度 | ≥ 11.4mg/mL in DMSO |
储存条件 | 4°C, protect from light |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
文献引用 | |
产品描述 | Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.Target: AntibacterialLevofloxacin reduced bacterial load compared with placebo by 4.9-fold (95% confidence interval, 1.4-25.7; P=0.02) at day 7 but had no effect at any point on any marker of neutrophilic airway inflammation. In patients with a baseline bacterial load of more than 10(6) cfu/mL, levofloxacin treatment was associated with a 26.5% (95% confidence interval, 1.8%-51.3%; P=0.04) greater reduction in the percentage neutrophil count compared with placebo at day 7 [1]. Levofloxacin was found to significantly improve the clinical and microbiological parameters in CP individuals [2]. A 30-day course of levofloxacin does not significantly improve BK viral load reduction or allograft function when used in addition to overall reduction of immunosuppression [3]. References: |